Cadrenal TherapeuticsCVKD
13F holders, Q3 2025 (September 30)17holders +3
5new positions
2sold out
1famous investor
$13.78avg. 13F price*
At the end of Q3 2025, 17 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, up 3 from Q2 2025. 5 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($747K), Citadel Advisors ($274K) and LPL Financial LLC ($196K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $580K |
| Exits | 2 | $25K |
All 13F filers, Q2 2025 → Q3 2025: 48,204 shares bought and 2,358 shares sold, net +45,846 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Vanguard Group Inc. | 0.00% | Add +11.6% | 54,239 | $747K |
| Citadel Advisors | 0.00% | New | 19,864 | $274K |
| LPL Financial LLC | 0.00% | New | 14,200 | $196K |
| Geode Capital Management, LLC | 0.00% | No change | 12,710 | $175K |
| JPMorgan Chase & Co. | 0.00% | New | 7,500 | $103K |
| BlackRock, Inc. | 0.00% | Add +2.9% | 3,378 | $47K |
| Morgan Stanley | 0.00% | Add +104.7% | 880 | $12K |
| Osaic Holdings, Inc. | 0.00% | No change | 500 | $6K |
| Rockefeller Capital Management L.P. | 0.00% | New | 300 | $4K |
| Jones Financial Companies LLLP | 0.00% | No change | 172 | $2K |
| Clearstead Advisors, LLC | 0.00% | New | 150 | $2K |
| Harbour Investments, Inc. | 0.00% | No change | 100 | $1K |
| Wells Fargo & Company | 0.00% | Reduce -1.0% | 99 | $1K |
| Archer Investment Corp | 0.00% | No change | 35 | $484 |
| UBS Group AG | 0.00% | Reduce -89.3% | 35 | $484 |
| IFP Advisors, Inc | 0.00% | No change | 30 | $415 |
| Bank of America Corp. | 0.00% | Reduce -92.9% | 1 | $14 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.